BioVie Inc. (BIVI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Cuong Viet Do M.B.A. | President, CEO & Director | 618k | -- | 1966 |
| Ms. Joanne Wendy Kim CPA | CFO, Treasurer & Corporate Secretary | 270k | -- | 1955 |
| Dr. Joseph M. Palumbo M.D. | Executive VP of R&D and Chief Medical Officer | 560k | -- | 1960 |
| Mr. Clarence N. Ahlem | Senior Vice President of Operations | -- | -- | 1955 |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program | -- | -- | 1966 |
| Ms. Denise Smith | Senior Vice President of Manufacturing & Development | -- | -- | -- |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program | -- | -- | 1948 |
BioVie Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Corporate Governance
Upcoming Events
May 12, 2025 at 8:00 PM UTC - May 16, 2025 at 8:00 PM UTC
BioVie Inc. Earnings Date
Recent Events
November 29, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission